GO:0071560 cellular response to transforming growth factor beta stimulus: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071560 describes how a single cell changes its state or activity after receiving a transforming growth factor beta (TGF-beta) signal.
• The pathway is canonically initiated when TGF-beta ligands engage TGFBR2 and TGFBR1, leading to SMAD2/3 phosphorylation and SMAD4-dependent transcription.
• TGF-beta signaling is a master regulator of fibrosis, immune tolerance, and epithelial-to-mesenchymal transition in multiple organs [3,4,8].
• Dysregulated cellular TGF-beta responses contribute to liver fibrosis, cardiac fibrosis, autoimmune hepatitis, and pulmonary endothelial remodeling [3,4,7,8].
• Chromatin readers such as BRD4 and metabolic enzymes such as eicosanoid-degrading enzymes modulate the intensity of TGF-beta-driven transcriptional programs [4,5].
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of individual genes within the GO:0071560 response [3,5].
Description
The Gene Ontology term GO:0071560, cellular response to transforming growth factor beta stimulus, defines any process that changes the state or activity of a cell in terms of movement, secretion, enzyme production, gene expression, or other outputs as a result of a transforming growth factor beta stimulus. TGF-beta is a pleiotropic cytokine that instructs context-dependent programs ranging from growth arrest and differentiation to extracellular matrix production and immune modulation [3,7]. Because the response is cell-autonomous, GO:0071560 is the appropriate annotation for experiments that treat a defined cell population with TGF-beta and measure downstream molecular or phenotypic changes [3,5]. Researchers care about GO:0071560 because it sits at the intersection of fibrosis, cancer, autoimmunity, and vascular remodeling [3,4,7,8]. In liver fibrosis models, TGF-beta/Smad signaling drives hepatic stellate cell activation and collagen deposition, and pharmacological inhibition of this axis reduces injury. In the heart, TGF-beta-responsive cardiac fibroblasts acquire a myofibroblast phenotype that is epigenetically reinforced by BRD4. In autoimmune hepatitis, TGF-beta participates in the cytokine network that shapes loss of tolerance and chronic inflammation. In the lung vasculature, store-operated calcium entry contributes to endothelial-to-mesenchymal transition downstream of TGF-beta-related cues. Mechanistically, the cellular response to TGF-beta is not a single linear cascade but a network of ligand-receptor interactions, SMAD and non-SMAD signaling, chromatin remodeling, and metabolic feedback [3,4,5]. This article summarizes the QuickGO definition, the major signaling stages, the key genes and proteins, disease links, and the CRISPR-based methods used to dissect the pathway [3,4,5,8].
cellular response to transforming growth factor beta stimulus At A Glance
| GO ID | GO:0071560 |
|---|---|
| GO term | cellular response to transforming growth factor beta stimulus |
| Ontology | biological_process |
| Synonym | cellular response to TGF-beta stimulus; cellular response to TGFbeta stimulus |
| Definition | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus. |
| Major function | Transduces extracellular TGF-beta signals into cell-autonomous changes in transcription, cytoskeleton, secretion, and metabolism [3,5]. |
| Parent-like context | Response to cytokine and response to growth factor signaling at the single-cell level. |
| Representative ligands | TGFB1, TGFB2, TGFB3 [3,7]. |
| Representative receptors | TGFBR1, TGFBR2. |
| Representative effectors | SMAD2, SMAD3, SMAD4, BRD4 [3,5]. |
What Is GO:0071560?
GO:0071560 is a biological process term meaning any process that results in a change in state or activity of a cell (for example movement, secretion, enzyme production, or gene expression) as a result of a transforming growth factor beta stimulus. It is a cellular-level response term, so it applies to a single cell type responding to TGF-beta rather than to a whole-organism or tissue-level process [3,5].
Why Is cellular response to transforming growth factor beta stimulus Important in Cell Biology?
GO:0071560 is important because TGF-beta is one of the most frequently dysregulated signaling inputs in human disease, and the cellular response determines whether a cell proliferates, arrests, migrates, secretes matrix, or changes identity [3,4,7,8]. Accurate annotation of this term enables researchers to compare transcriptomic and proteomic datasets across fibrosis, autoimmunity, and vascular disease models, and it provides a controlled vocabulary for CRISPR screens that interrogate TGF-beta responsiveness [3,5,8].
• TGF-beta/Smad signaling is a central driver of liver fibrosis and is attenuated by compounds such as aloin in CCl4-treated mice.
• Cardiac fibroblast activation and fibrosis depend on TGF-beta-responsive chromatin remodeling by BRD4.
• Eicosanoid degradation pathways modulate fibrosis of the heart, intersecting with TGF-beta-driven remodeling.
• Autoimmune hepatitis pathogenesis involves cytokine networks in which TGF-beta shapes immune tolerance and inflammation.
• Endothelial-to-mesenchymal transition in lung vascular cells involves store-operated calcium entry and TGF-beta-related programs.
• Microglia-mediated neuroinflammation, relevant to cardiovascular disease, is influenced by TGF-beta family signaling.
• Extracellular vesicle surface proteins such as GAS6/PROS1 and CD39/CD73 can attenuate inflammation, a process that intersects with TGF-beta responses.
• Sputum transcriptomics in eosinophilic asthma identifies macrophage activation states that may respond to TGF-beta cues.
• GO:0071560 provides a standardized annotation for CRISPR screens targeting TGF-beta response genes [3,5].
• The term supports cross-disease meta-analyses of fibrosis, autoimmunity, and vascular remodeling [3,4,7,8].
What Happens During cellular response to transforming growth factor beta stimulus?
Ligand binding and receptor activation
In simple terms: TGF-beta docks onto receptors on the cell surface and switches them on.
The cellular response begins when TGF-beta ligands bind the type II receptor TGFBR2, which recruits and phosphorylates the type I receptor TGFBR1. This receptor complex then propagates the signal inside the cell, converting an extracellular cue into an intracellular phosphorylation event. In fibrosis models, this step is a therapeutic target because blocking TGF-beta/Smad signaling reduces collagen deposition and injury.
SMAD phosphorylation and nuclear translocation
In simple terms: Messenger proteins are tagged and travel to the nucleus to change gene expression.
Activated TGFBR1 phosphorylates SMAD2 and SMAD3, which then associate with SMAD4 and translocate to the nucleus. In the nucleus, this complex regulates transcription of target genes involved in extracellular matrix production, growth arrest, and differentiation. The SMAD axis is the canonical effector arm of GO:0071560 and is frequently measured as phospho-SMAD2/3 in TGF-beta-treated cells.
Chromatin remodeling and transcriptional output
In simple terms: The DNA packaging is loosened so that TGF-beta target genes can be read.
TGF-beta-responsive transcription requires chromatin accessibility changes, and BRD4 dynamically targets chromatin to stimulate cardiac fibroblast activation. This epigenetic layer determines which cells execute a fibrotic versus a homeostatic program after TGF-beta stimulation. Thus, the cellular response includes not only SMAD activation but also the recruitment of chromatin readers that amplify or restrict the transcriptional output.
Non-SMAD and metabolic modulation
In simple terms: Other signaling and metabolic routes fine-tune the TGF-beta response.
Beyond SMADs, TGF-beta engages non-SMAD pathways and metabolic enzymes that shape the duration and intensity of the response. Inhibition of eicosanoid degradation mitigates fibrosis of the heart, indicating that lipid mediator turnover intersects with TGF-beta-driven remodeling. Store-operated calcium entry is also involved in endothelium-to-mesenchymal transition in lung vascular endothelial cells, linking calcium signaling to the cellular response.
Immune and inflammatory context
In simple terms: TGF-beta also tells immune cells whether to calm down or stay active.
TGF-beta is a key cytokine in immune regulation, and its cellular response influences autoimmune hepatitis pathogenesis and microglia-mediated neuroinflammation [1,7]. Extracellular vesicle surface proteins such as GAS6/PROS1 and CD39/CD73 attenuate inflammation, a process that can intersect with TGF-beta signaling in the tissue microenvironment. Sputum transcriptomics in eosinophilic asthma further highlights macrophage activation states that may respond to TGF-beta family cues.
Key Genes Involved in GO:0071560 cellular response to transforming growth factor beta stimulus
The following genes and proteins are representative components of the cellular response to TGF-beta and are commonly interrogated in functional studies [3,4,5,7,8].
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Prototype TGF-beta ligand | Central ligand for inducing GO:0071560 in vitro and in vivo. |
| TGFB2 | TGF-beta family ligand | Context-dependent ligand in fibrosis and vascular remodeling. |
| TGFB3 | TGF-beta family ligand | Modulates TGF-beta responses in development and repair. |
| TGFBR1 | Type I receptor kinase | Phosphorylates SMAD2/3 and is a drug target in fibrosis. |
| TGFBR2 | Type II receptor | Binds ligand and activates TGFBR1. |
| SMAD2 | Receptor-regulated SMAD | Transduces TGF-beta signals to the nucleus. |
| SMAD3 | Receptor-regulated SMAD | Key effector of fibrotic gene programs. |
| SMAD4 | Common SMAD | Forms complexes with SMAD2/3 for transcription. |
| BRD4 | Chromatin reader | Stimulates cardiac fibroblast activation downstream of TGF-beta. |
| GAS6 | EV surface protein | Attenuates inflammation in the tissue microenvironment. |
| PROS1 | EV surface protein | Modulates inflammatory signaling alongside GAS6. |
| CD39 | Ectonucleotidase | Regulates extracellular ATP and inflammation. |
| CD73 | Ectonucleotidase | Generates adenosine and dampens inflammation. |
| FCN1 | Macrophage marker | Identifies activated macrophage states in eosinophilic asthma. |
| SMAD7 | Inhibitory SMAD | Negative feedback regulator of TGF-beta signaling. |
| ACTA2 | Myofibroblast marker | Readout of TGF-beta-driven fibroblast activation. |
| COL1A1 | Extracellular matrix gene | Transcriptional target of TGF-beta/Smad signaling. |
| SERPINE1 | TGF-beta target gene | Common readout of SMAD transcriptional activity. |
How Is cellular response to transforming growth factor beta stimulus Regulated?
The cellular response to TGF-beta is regulated at multiple levels. Inhibitory SMAD7 provides negative feedback on receptor signaling. Chromatin-level control by BRD4 determines the magnitude of fibroblast activation after TGF-beta stimulation. Metabolic and lipid mediator pathways, including eicosanoid degradation, modulate the fibrotic output of TGF-beta responses. Calcium signaling through store-operated calcium entry contributes to endothelial-to-mesenchymal transition, adding another layer of regulation. In immune contexts, extracellular vesicle surface proteins such as GAS6/PROS1 and CD39/CD73 attenuate inflammation and thereby shape the net cellular response.
cellular response to transforming growth factor beta stimulus and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Liver fibrosis | TGFB1 overexpression or KO in hepatic stellate cells. |
| SMAD3 | Cardiac fibrosis | SMAD3 KO in cardiac fibroblasts with TGF-beta treatment. |
| BRD4 | Cardiac fibroblast activation | BRD4 point-mutation or KO in fibroblasts. |
| TGFBR1 | Pulmonary vascular remodeling | TGFBR1 KO in lung endothelial cells. |
| SMAD7 | Autoimmune hepatitis | SMAD7 overexpression in immune or hepatic cells. |
Liver fibrosis and TGF-beta/Smad signaling
Liver fibrosis is driven by TGF-beta/Smad signaling, and compounds such as aloin attenuate oxidative stress, inflammation, and CCl4-induced liver fibrosis in mice through this pathway. The cellular response to TGF-beta in hepatic stellate cells promotes extracellular matrix gene expression and myofibroblast differentiation. Targeting GO:0071560 components is therefore a rational strategy for antifibrotic therapy.
Cardiac fibrosis and chromatin control
In the heart, TGF-beta stimulates cardiac fibroblast activation, and BRD4 dynamically targets chromatin to sustain this program. Inhibition of eicosanoid degradation mitigates fibrosis of the heart, showing that metabolic regulation intersects with TGF-beta-driven remodeling. These findings position GO:0071560 as a central node in cardiac fibrosis research [4,5].
Autoimmune hepatitis and immune regulation
Autoimmune hepatitis pathogenesis involves cytokine networks in which TGF-beta contributes to immune tolerance and inflammation. The cellular response to TGF-beta in immune and hepatic cells influences disease progression and treatment response. Microglia-mediated neuroinflammation, relevant to cardiovascular disease, is also modulated by TGF-beta family signaling.
Pulmonary vascular remodeling and endothelial transition
Store-operated calcium entry is involved in endothelium-to-mesenchymal transition in lung vascular endothelial cells, a process linked to TGF-beta-related cues. This highlights how GO:0071560 contributes to vascular remodeling and pulmonary disease. Extracellular vesicle surface proteins that attenuate inflammation may further modify this response.
From cellular response to transforming growth factor beta stimulus-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for TGF-beta-induced transcription? | CRISPR knockout in a TGF-beta-responsive cell line. |
| Does a specific phospho-site control SMAD activity? | Point mutation of SMAD2/3 phosphorylation sites. |
| Can a disease-associated variant alter TGF-beta response? | Knock-in of the variant allele followed by TGF-beta stimulation. |
| Where does a protein localize after TGF-beta treatment? | Tagged knock-in with fluorescent or epitope tag. |
| Does overexpression of an inhibitor block fibrosis? | Overexpression of SMAD7 or related inhibitors. |
| Which chromatin readers are needed for fibroblast activation? | CRISPR knockout of BRD4 and related readers. |
How to Study the cellular response to transforming growth factor beta stimulus Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes after TGF-beta | Defining GO:0071560 target genes. |
| Phospho-SMAD Western blot | SMAD2/3 activation | Validating receptor pathway engagement. |
| ChIP-seq | Chromatin binding of BRD4 and SMADs | Mapping epigenetic control of fibroblast activation. |
| ATAC-seq | Chromatin accessibility | Identifying TGF-beta-responsive regulatory regions. |
| Calcium imaging | Store-operated calcium entry | Studying endothelial-to-mesenchymal transition. |
| Extracellular vesicle profiling | GAS6/PROS1 and CD39/CD73 surface proteins | Assessing inflammation attenuation. |
| Sputum transcriptomics | Macrophage activation states | Asthma and airway inflammation research. |
| Immunofluorescence | Protein localization and marker expression | Confirming myofibroblast conversion. |
Transcriptomic profiling of TGF-beta response
RNA-seq before and after TGF-beta stimulation identifies the gene expression changes that define GO:0071560. This approach is used in fibrosis models to detect extracellular matrix and inflammatory genes. Sputum transcriptomics has also been used to characterize macrophage activation states relevant to TGF-beta responses.
Phospho-SMAD and signaling assays
Western blotting for phospho-SMAD2/3 is a standard readout of receptor activation after TGF-beta treatment. Combining this with SMAD4 co-immunoprecipitation confirms canonical pathway engagement. These assays are essential for validating CRISPR models of GO:0071560.
Chromatin and epigenetic readouts
Chromatin immunoprecipitation and ATAC-seq measure how BRD4 and other readers bind TGF-beta-responsive loci. These methods reveal the epigenetic layer that controls fibroblast activation. They are particularly useful when studying cell-type-specific responses.
Functional and imaging assays
Calcium imaging and store-operated calcium entry assays link calcium signaling to endothelial-to-mesenchymal transition. Extracellular vesicle profiling can assess GAS6/PROS1 and CD39/CD73 surface proteins that modulate inflammation. These functional assays complement molecular readouts of GO:0071560 [2,8].
How CRISPR Can Be Used to Study GO:0071560 cellular response to transforming growth factor beta stimulus
Knockout
CRISPR knockout of TGFBR1, SMAD3, or BRD4 can test whether a gene is required for the cellular response to TGF-beta [3,5]. Knockout clones are stimulated with TGF-beta and assayed for phospho-SMAD, target gene expression, and phenotypic changes. This approach is widely used in fibrosis and vascular remodeling research [3,8].
Point Mutation
Point mutation of phosphorylation sites in SMAD2 or SMAD3 can dissect which residues are essential for transcriptional output. CRISPR point-mutation models preserve endogenous expression levels while altering a single amino acid. They are valuable for studying disease-associated variants in TGF-beta pathway genes.
Knock-in
Knock-in of fluorescent or epitope tags allows live-cell tracking of SMAD or BRD4 dynamics after TGF-beta stimulation. Knock-in of disease variants can reveal allele-specific effects on GO:0071560. These models are especially useful for imaging and chromatin studies.
Overexpression
Overexpression of inhibitory SMAD7 or other negative regulators can suppress TGF-beta-driven fibrosis programs. Overexpression models are used to test whether a candidate gene is sufficient to alter the cellular response. They complement knockout studies by providing gain-of-function evidence.
How EDITGENE Supports cellular response to transforming growth factor beta stimulus Research
Researchers studying cellular response to transforming growth factor beta stimulus-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with it. EDITGENE provides CRISPR-based cell model services that enable loss-of-function, gain-of-function, and variant-specific experiments in TGF-beta-responsive cell types [3,5].
Contact EDITGENE today to design your custom CRISPR model for cellular response to transforming growth factor beta stimulus research.
Frequently Asked Questions About cellular response to transforming growth factor beta stimulus
What is GO:0071560?
GO:0071560 is the Gene Ontology term for cellular response to transforming growth factor beta stimulus, defined as any process that changes a cell's state or activity as a result of a TGF-beta stimulus.
What genes are involved in cellular response to transforming growth factor beta stimulus?
Key genes include TGFB1, TGFBR1, TGFBR2, SMAD2, SMAD3, SMAD4, SMAD7, and BRD4 [3,5].
What does TGF-beta do to a cell?
TGF-beta can alter gene expression, movement, secretion, and enzyme production, often through SMAD2/3 and SMAD4-dependent transcription.
How is the cellular response to TGF-beta measured?
Common readouts include phospho-SMAD2/3 Western blotting, RNA-seq of target genes, and chromatin assays such as ChIP-seq [3,5].
Is GO:0071560 involved in fibrosis?
Yes, TGF-beta/Smad signaling drives liver fibrosis and cardiac fibroblast activation, and inhibition of this pathway reduces fibrosis in models [3,4,5].
What is the role of BRD4 in TGF-beta response?
BRD4 dynamically targets chromatin to stimulate cardiac fibroblast activation downstream of TGF-beta.
Can CRISPR knockout help study GO:0071560?
Yes, CRISPR knockout of TGFBR1, SMAD3, or BRD4 can test whether a gene is required for the cellular response to TGF-beta [3,5].
What diseases are linked to TGF-beta signaling?
TGF-beta signaling is linked to liver fibrosis, cardiac fibrosis, autoimmune hepatitis, and pulmonary vascular remodeling [3,4,7,8].
What is the difference between GO:0071560 and response to TGF-beta?
GO:0071560 is the cellular-level response term, focusing on changes within a single cell after TGF-beta stimulation.
How do I choose a model to study TGF-beta response?
The choice depends on the question: knockout for requirement, point mutation for mechanism, knock-in for localization, and overexpression for sufficiency [3,5].
Conclusion
GO:0071560, cellular response to transforming growth factor beta stimulus, is a central biological process term for understanding how cells interpret TGF-beta signals. Its canonical SMAD pathway, chromatin-level regulation, and metabolic intersections make it relevant to fibrosis, autoimmunity, and vascular disease [3,4,5,7,8]. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide causal evidence for the roles of individual genes within this response [3,5]. Researchers can use these models to link genotype to TGF-beta-dependent phenotypes in a controlled and reproducible manner [3,5].
References
- 1. Wang M et al.. 2022. Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.. J Inflamm Res 15:3083-3094 PMID: 35642214
- 2. Fabiano MP et al.. 2025. Plasma extracellular vesicle surface-located GAS6/PROS1 and CD39/CD73 attenuate inflammation.. Cell Rep 44(8):116096 PMID: 40751911
- 3. Bai J et al.. 2023. Aloin Attenuates Oxidative Stress, Inflammation, and CCl(4)-Induced Liver Fibrosis in Mice: Possible Role of TGF-β/Smad Signaling.. J Agric Food Chem 71(49):19475-19487 PMID: 38038700
- 4. Rubino M et al.. 2023. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart.. Circ Res 132(1):10-29 PMID: 36475698
- 5. Stratton MS et al.. 2019. Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation.. Circ Res 125(7):662-677 PMID: 31409188
- 6. Zhan W et al.. 2024. Sputum Transcriptomics Reveals FCN1+ Macrophage Activation in Mild Eosinophilic Asthma Compared to Non-Asthmatic Eosinophilic Bronchitis.. Allergy Asthma Immunol Res 16(1):55-70 PMID: 38262391
- 7. Vergani D et al.. 2008. Aetiopathogenesis of autoimmune hepatitis.. World J Gastroenterol 14(21):3306-12 PMID: 18528928
- 8. Babicheva A et al.. 2025. Store-operated Ca(2+) entry is involved in endothelium-to-mesenchymal transition in lung vascular endothelial cells.. Am J Physiol Lung Cell Mol Physiol 328(6):L844-L857 PMID: 40331589
